• Profile
Close

Preoperative radiotherapy plus surgery vs surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): A multicentre, open-label, randomised, phase 3 trial

The Lancet Oncology Sep 18, 2020

Bonvalot S, Gronchi A, Le Péchoux C, et al. - Researchers investigated the effect of preoperative radiotherapy plus surgery vs surgery alone on abdominal recurrence-free survival of patients suffering from primary retroperitoneal sarcoma, in this open-label, randomised, phase 3 study (EORTC-62092). This study was done in 13 countries in Europe and North America. Eligible patients were randomized (1:1) to receive either surgery alone or preoperative radiotherapy followed by surgery. In the radiotherapy plus surgery group and in the surgery only group, the median abdominal recurrence-free survival was found to be 4·5 years and 5·0 years, respectively. In 30 (24%) of 127 patients in the radiotherapy plus surgery group and in 13 (10%) of 128 patients in the surgery alone group, serious adverse events were experienced. Based on these findings, experts recommended not considering preoperative radiotherapy as standard of care treatment for retroperitoneal sarcoma.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay